Patient-reported outcome results in patients with type 2 diabetes treated with once-weekly dulaglutide: data from the AWARD phase III clinical trial programme

Efficacy and Safety of Once-Weekly Dulaglutide Versus Insulin Glargine in Patients With Type 2 Diabetes on Metformin and Glimepiride (AWARD-2)

(2015) Francesco Giorgino et al.   DIABETES CARE

Treatment satisfaction in people with type 2 diabetes mellitus treated with once-weekly dulaglutide: data from the AWARD-1 and AWARD-3 clinical trials

(2015) M. Reaney et al.   DIABETES OBESITY & METABOLISM

Safety and efficacy of once-weekly dulaglutide versus sitagliptin after 2 years in metformin-treated patients with type 2 diabetes (AWARD-5): a randomized, phase III study

(2015) R. S. Weinstock et al.   DIABETES OBESITY & METABOLISM

Reliability, Validity, and Responsiveness of the Impact of Weight on Self-Perceptions Questionnaire (IW-SP) in Individuals with Type 2 Diabetes and Obesity

(2015) Risa P. Hayes et al.   Diabetes Technology & Therapeutics

Once-weekly dulaglutide versus bedtime insulin glargine, both in combination with prandial insulin lispro, in patients with type 2 diabetes (AWARD-4): a randomised, open-label, phase 3, non-inferiority study

(2015) Lawrence Blonde et al.   LANCET

Efficacy and Safety of Dulaglutide Monotherapy Versus Metformin in Type 2 Diabetes in a Randomized Controlled Trial (AWARD-3)

(2014) Guillermo Umpierrez et al.   DIABETES CARE

Efficacy and Safety of Dulaglutide Added Onto Pioglitazone and Metformin Versus Exenatide in Type 2 Diabetes in a Randomized Controlled Trial (AWARD-1)

(2014) Carol Wysham et al.   DIABETES CARE

Efficacy and Safety of Dulaglutide Versus Sitagliptin After 52 Weeks in Type 2 Diabetes in a Randomized Controlled Trial (AWARD-5)

(2014) Michael Nauck et al.   DIABETES CARE

Once-weekly dulaglutide versus once-daily liraglutide in metformin-treated patients with type 2 diabetes (AWARD-6): a randomised, open-label, phase 3, non-inferiority trial

(2014) Kathleen M Dungan et al.   LANCET

Test–Retest, Responsiveness, and Minimal Important Change of the Ability to Perform Physical Activities of Daily Living Questionnaire in Individuals with Type 2 Diabetes and Obesity

(2012) Risa P. Hayes et al.   Diabetes Technology & Therapeutics

A literature review to explore the link between treatment satisfaction and adherence, compliance, and persistence

(2012) Carla Dias-Barbosa et al.   Patient Preference and Adherence

LY2189265, a long-acting glucagon-like peptide-1 analogue, showed a dose-dependent effect on insulin secretion in healthy subjects

(2011) P. Barrington et al.   DIABETES OBESITY & METABOLISM

A 5-week study of the pharmacokinetics and pharmacodynamics of LY2189265, a novel, long-acting glucagon-like peptide-1 analogue, in patients with type 2 diabetes

(2011) P. Barrington et al.   DIABETES OBESITY & METABOLISM

Improved treatment satisfaction and weight-related quality of life with exenatide once weekly or twice daily

(2009) J. H. Best et al.   DIABETIC MEDICINE